TIAA CREF Investment Management LLC raised its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 14.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 110,076 shares of the biotechnology company’s stock after buying an additional 13,825 shares during the period. TIAA CREF Investment Management LLC owned about 0.27% of Seres Therapeutics worth $1,241,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MCRB. JPMorgan Chase & Co. boosted its stake in Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after buying an additional 50,860 shares during the period. State Street Corp boosted its stake in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 16,671 shares during the period. Spark Investment Management LLC acquired a new stake in Seres Therapeutics during the first quarter worth about $613,000. Teachers Advisors LLC boosted its stake in Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after buying an additional 12,462 shares during the period. Finally, American Century Companies Inc. acquired a new stake in Seres Therapeutics during the first quarter worth about $447,000. Hedge funds and other institutional investors own 75.28% of the company’s stock.

Shares of Seres Therapeutics, Inc. (NASDAQ MCRB) traded up 0.36% during midday trading on Tuesday, reaching $13.75. 4,084 shares of the company’s stock traded hands. The stock’s market cap is $557.04 million. Seres Therapeutics, Inc. has a 52-week low of $8.85 and a 52-week high of $15.09. The stock has a 50 day moving average of $12.61 and a 200-day moving average of $10.72.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.70) EPS. On average, equities research analysts expect that Seres Therapeutics, Inc. will post ($2.48) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/15/tiaa-cref-investment-management-llc-has-1-24-million-position-in-seres-therapeutics-inc-mcrb.html.

A number of equities analysts have recently commented on the stock. BidaskClub lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Zacks Investment Research lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.